Radiation Resistance Correlates With PD-L1 Expression in HNSCC

Share this content:
A tissue array of head and neck tumor samples demonstrated a significant association between locoregional recurrence and PD-L1 expression.
A tissue array of head and neck tumor samples demonstrated a significant association between locoregional recurrence and PD-L1 expression.

PD-L1 tumor expression is modulated by Axl and PI3K signaling, and may be a biomarker of radiation response among patients with HPV-negative head and neck squamous cell carcinoma (HNSCC), according to a study published in Clinical Cancer Research.1

Though it is believed that a functioning immune response is needed for optimal response to radiation, the role of this response is not yet understood. This study investigated potential mechanisms associated with immune response and loss of response to radiotherapy.

Radiation resistance was induced in HPV-negative HNSCC cell lines by repeated radiation exposure. Protein expression of Axl, phosphorylated-Axl, PD-L1, and markers of the PI3K/AKT/mTOR pathway were increased in the radiation-resistant cells, but not the parent cell line, which was not radiation resistant.

The radiation-resistant cell lines also showed a correlation between Axl and PD-L1 expression. Inhibition of Axl or PI3K with a chemical agent or siRNA resulted in decreased PD-L1 expression compared with vehicle control.

The study also collected tumor samples from 3 cohorts of patients with HPV-negative HNSCC who had undergone radiotherapy; 2 of the cohorts included 68 and 97 patients with locally advanced disease, and the third cohort was from The Cancer Genome Atlas.

The investigators also found a correlation between Axl and PD-L1 expression among these tumor samples.

RELATED: Phase 1/2 Study of Tadalafil + Vaccine in HNSCC

A tissue array of the tumor samples demonstrated a significant association between locoregional recurrence (LRR) and PD-L1 expression (P = .021). Three-year LRR rates were significantly higher among patients with high PD-L1 expression (50%) compared with low PD-L1 expression (20%; P = .0009).

Reference

  1. Skinner HD, Giri U, Yang LP, et al. Integrative analysis identifies a novel AXL-PI3 kinase–PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res. 2017 May 5. doi: 10.1158/1078-0432.CCR-16-2586 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters